z-logo
open-access-imgOpen Access
Low Expression of miR-663a Indicates Poor Prognosis and Promotes Cell Proliferation, Migration, and Invasion in Breast Cancer
Author(s) -
Gang Wang,
Lei Chen,
Jihong Wei,
Lin Fang
Publication year - 2021
Publication title -
oncology research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.553
H-Index - 48
eISSN - 2296-5262
pISSN - 2296-5270
DOI - 10.1159/000513405
Subject(s) - breast cancer , cancer research , cancer , microrna , cell growth , biology , medicine , metastasis , oncology , gene , genetics
Breast cancer is one of the most common malignant cancers among women worldwide. MicroRNA-663a (miR-663a) acts as a tumor suppressor gene involved in the development of various cancers. Objective: The aim of this study was to reveal the clinical significance and biological function of miR-663a in breast cancer. Methods: The expression of miR-663a in breast cancer tissues and cells was evaluated by reverse transcription-quantitative polymerase chain reaction. Kaplan-Meier survival and Cox regression analysis were performed to evaluate the prognostic significance of miR-663a in breast cancer. CCK-8 and Transwell assays were used to demonstrate the effect of miR-663a on breast cancer cell function. Results: We confirmed that the expression of miR-663a was significantly downregulated in breast cancer tissue samples and cell lines. Low miR-663a expression was significantly associated with lymph node metastasis, TNM stage, subtypes, and poor survival in breast cancer patients, indicating that miR-663a is an independent prognostic factor for patients with breast cancer. Cell function experiments revealed that low miR-663a expression promoted cell proliferation, migration, and invasion in breast cancer. Conclusions: All experimental results demonstrated that miR-663a acts as a tumor suppressor that inhibits the proliferation, migration, and invasion of breast cancer cells, and miR-663a may be a prognostic biomarker and therapeutic target for breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here